| Impel NeuroPharma, Inc. |
77530072504 |
TRUDHESA™, DHE Nasal Spray, 1.45mg, 4 single-dose units |
2021-09-17 |
850.0000 |
None |
1 |
67000 |
None |
None |
None |
None |
None |
None |
1= Proprietary, non public information |
None |
| Incyte Corporation |
50881000705 |
Opzelura (ruxolitinib) cream 1.5% 60gm tube |
2021-10-04 |
1950.0000 |
"To market OPZELURA, Incyte designed activities to increase awareness and understanding with healthcare providers about OPZELURA. Marketing activities will include education and training provided by our sales force and by contracted speakers to health care providers. Consumer-directed communications to educate patients on the disease state and OPZELURA are planned. At Incyte, we are driven by rigorous science and committed to ensuring patients have access to our innovative medicines. We responsibly price our drugs by balancing the value of the outcomes and innovation they bring to patients and the health care system within market and societal expectations.
OPZELURA is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Use of OPZELURA in combination with therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine is not recommended." |
None |
5500000 |
None |
1 |
None |
None |
None |
None |
Comment regarding Field 7: Provide source of population data (e.g. IQVIA) or explanation "Incyte's estimated volume of patients who may be prescribed OPZELURA is not available in the public domain. Estimated population is derived from the following publically available information . . ." Comment regarding Fields 8 and 9: Acquisition fields left blank as drug was developed by Incyte. General Comment: In the event 2017 California Senate Bill 17 (“SB-17”) and the laws it implements, including Cal. Health & Safety Code § 127677, are found unconstitutional or otherwise unlawful, Incyte reserves all of its legal rights. In issuing this report in an attempt to comply with Cal. Health & Safety Code § 127677, Incyte does not waive any legal claims or legal rights related to SB-17. Please note that portions of this report and its contents may be exempted from disclosure under the California Public Records Act, Cal. Gov. Code § 6250 et seq. (“PRA”) as the material contains and constitutes Incyte’s proprietary commercial information and otherwise would not be in the public interest to disclose. We ask that you please contact the Incyte legal department at 1801 Augustine Cut-Off, Wilmington, DE 19803 if you receive any PRA requests so that we may take appropriate steps to work with you to protect such information. |
None |
| Ingenus Pharmaceuticals, LLC |
50742052110 |
Cyclophosphamide 200mg 10ml Injection |
2021-12-17 |
1465.0000 |
Ingenus prices their products based on the current market conditions along with a number of variables. All of these product specific variables are entered into a pricing model and pricing is determined. Some examples ( not all ) are cost of goods, profit share, freight costs, product volume, customer specific volumes, the COT/channels the specific product is sold in, rebates, chargebacks, contractual obligations. These factors vary product by product and aren’t all applicable in every case. |
None |
30000 |
None |
None |
None |
None |
None |
None |
As a manufacturer, Ingenus does not estimate the number of patients that may be prescribed our products. We manufacturer volume based on an estimated market share and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. Acquisition is not applicable. |
None |